12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zaltrap aflibercept regulatory update

Germany's Federal Joint Committee (G-BA) said Zaltrap aflibercept from Sanofi has "marginal" additional benefit to treat metastatic colorectal cancer (mCRC) vs. FOLFIRI chemotherapy. G-BA's final benefit assessment is in line with a...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >